Jyong Biotech Ltd. Ordinary Shares (MENS) Earnings History
Net Loss5 years of earnings data (2020–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Jyong Biotech Ltd. Ordinary Shares (MENS) Earnings Overview
As of June 21, 2026, Jyong Biotech Ltd. Ordinary Shares (MENS) reported trailing twelve-month net income of -$3,019, reflecting +31.4% year-over-year growth. The company earned $-0.04 per diluted share over the past four quarters.
Looking at the long-term picture, MENS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2020.
Jyong Biotech Ltd. Ordinary Shares is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AEYE (-$4M net income, -7.6% margin), NUVB (-$146M net income, -325.3% margin), HALO ($349M net income, 22.7% margin), MENS has comparable earnings metrics. Compare MENS vs AEYE →
MENS Earnings vs Peers
Earnings metrics vs comparable public companies
MENS Historical Earnings Data (2020–2024)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$3M | +31.4% | -$2M | $-0.04 | - | - |
| 2023 | -$4M | +33.6% | -$3M | $-0.06 | - | - |
| 2022 | -$7M | -57.9% | -$3M | $-0.09 | - | - |
| 2021 | -$4M | -119.1% | -$2M | $-0.06 | - | - |
| 2020 | -$2M | - | -$2M | $-0.03 | - | - |
Download Data
Export MENS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MENS — Frequently Asked Questions
Quick answers to the most common questions about buying MENS stock.
What is MENS earnings per share (EPS)?
MENS trailing twelve-month (TTM) diluted EPS is $-0.04, reflecting +31.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2024 is available in the table on this page.
What is Jyong Biotech Ltd. Ordinary Shares's net income?
Jyong Biotech Ltd. Ordinary Shares (MENS) trailing twelve-month net income is $-3019.00 as of 2024. Earnings grew +31.4% year-over-year.
Is MENS profitable?
MENS is not currently profitable on a TTM basis, reporting a net loss of $-3019.00. Net margin is N/A. Investors should monitor for a return to profitability.
What is MENS's earnings growth rate?
MENS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2024.
What are MENS's profit margins?
Jyong Biotech Ltd. Ordinary Shares net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is MENS growing earnings?
Yes, MENS earnings are accelerating — EPS growth of +31.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-3019.00. Earnings momentum is strengthening.
What was MENS's best earnings year?
Jyong Biotech Ltd. Ordinary Shares's highest annual net income on record is $-2M, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2024 and includes all annual and quarterly figures.
What were MENS's earnings last quarter?
MENS's most recent reported quarter was Q4 2024. Net income was $-847.00 with diluted EPS of $-0.01. For a full breakdown of all quarters, see the quarterly earnings table on this page.